SME Times is powered by   
Search News
Just in:   • Biden administration forgives $4.7 billion loans to Ukraine  • Women entrepreneurs driving innovation, growth in gem & jewellery sector: Smriti Irani  • India’s export outlook brighter as manufactured goods gain share: RBI  • India’s consumer durable makers to log 11-12 pc growth in FY25  • SEBI’s proposal on SME IPOs: striking a delicate balance 
Last updated: 14 Dec, 2017  

Cipla's Digital Transformation Continues: Launches 2 Digital Education Platforms

Business Wire India | 13 Dec, 2017
Business Wire India
In continuation to its commitment to patient-centricity & digitization, Cipla announces the launch of 2 digital assets; one aimed at healthcare professionals & the other at patients – Ciplamed & Breathefree respectively.
 
While CME's remains a critical component of our healthcare system, low physician to patient ratio in the Indian setting most often leaves the physician very little time for any extra educational engagements. On the other side, the new digital era also presents opportunity to learn & sharpen skills through alternate channels as per one’s convenience.
 
The all new Ciplamed is a uniquely designed comprehensive medical portal for healthcare professionals, available as a mobile app (Android & iOS) and a mobile-responsive website. Ciplamed offers a range of scientific resources such as eCMEs, infographics, presentations, medical news, patient education material and much more across specialities to keep oneself updated with the new advances in the medical field. Ciplamed aims to offer reliable medical information on-the-go to the time-crunched physicians, to promote best clinical practice and improved health outcomes.
 
Ciplamed App (Android) – Click here

Ciplamed App (iOS) – Click here

Website link: www.ciplamed.com

While the nation encounters a steady rise in breathing related problems, people are seeking credible & vital information on their disease conditions & its management.
 
The new Breathefree website will continue to be a complete and comprehensive source of patient information tool relating to breathing disorders and is also designed to be a powerful, closely connected community of people suffering from various breathing ailments. So, while anyone can, of course, learn everything about a breathing issue that may be bothering them, it also provides a powerful platform for people to share experiences, insights and stories of personal triumphs.
 
Breathefree Website link – Click here
 
Nikhil Chopra, Head India Business, Cipla, "Continuing Cipla's commitment towards patient centricity & Innovation; we are happy to bring to life 2 great educational efforts delivered through a digital route. We hope these assets will empower better healthcare decisions & outcomes."
 
Kiran Pai, Head Digital Marketing, Cipla, "Simplified content & great user interface is the hallmark of new age digital education platforms & we have tried to do just that with Ciplamed & breathe free platforms. Needless to mention that both platforms are mobile responsive to fuel consumption across the mobile first segment."
 
Dr Jaideep Gogaty, Chief Medical Officer, Cipla "Cipla has always partnered with the medical fraternity towards enhancing patient care. Ciplamed and Breathefree are two unique initiatives in this continuing endeavour. While Ciplamed provides a wide range of comprehensive and practice-oriented medical resources and updates for the busy healthcare professional, Breathefree aims to enhance patient awareness on asthma, COPD and allergic rhinitis in a lucid and user-friendly format."
 
Print the Page Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
84.35
82.60
UK Pound
106.35
102.90
Euro
92.50
89.35
Japanese Yen 55.05 53.40
As on 12 Oct, 2024
  Daily Poll
Will the new MSME credit assessment model simplify financing?
 Yes
 No
 Can't say
  Commented Stories
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter